Atezolizumab and Bevacizumab in Hepatocellular Carcinoma

被引：0
|
作者：
Hizal, Mutlu [1 ]
Sendur, Mehmet A. N. [2 ]
Yalcin, Bulent [2 ]
机构：
[1] Ankara City Hosp, Ankara, Turkey
[2] Yildirim Beyazit Univ, Ankara, Turkey
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2020年 / 383卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：694 / 694
页数：1
相关论文
共 50 条
  • [21] INTESTINAL MICROBIOME ASSOCIATED WITH EFFICACY OF ATEZOLIZUMAB AND BEVACIZUMAB THERAPY FOR HEPATOCELLULAR CARCINOMA
    Inukai, Yosuke
    Yamamoto, Kenta
    Honda, Takashi
    Yokoyama, Shinya
    Ito, Takanori
    Imai, Norihiro
    Ishizu, Yoji
    Nakamura, Masanao
    Ishigami, Masatoshi
    Kawashima, Hiroki
    HEPATOLOGY, 2023, 78 : S1273 - S1273
  • [22] Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: the DEMAND trial protocol
    Ben Khaled, Najib
    Seidensticker, Max
    Ricke, Jens
    Mayerle, Julia
    Oehrle, Bettina
    Roessler, Daniel
    Teupser, Daniel
    Ehmer, Ursula
    Bitzer, Michael
    Waldschmidt, Dirk
    Fuchs, Martin
    Reuken, Philipp A.
    Lange, Christian M.
    Wege, Henning
    Kandulski, Arne
    Dechene, Alexander
    Venerito, Marino
    Berres, Marie-Luise
    Luedde, Tom
    Kubisch, Ilja
    Reiter, Florian P.
    De Toni, Enrico N.
    FUTURE ONCOLOGY, 2022, 18 (12) : 1423 - 1435
  • [23] Intestinal Microbiome Associated with Efficacy of Atezolizumab and Bevacizumab Therapy for Hepatocellular Carcinoma
    Inukai, Yosuke
    Yamamoto, Kenta
    Honda, Takashi
    Yokoyama, Shinya
    Ito, Takanori
    Imai, Norihiro
    Ishizu, Yoji
    Nakamura, Masanao
    Ishigami, Masatoshi
    Kawashima, Hiroki
    CANCERS, 2024, 16 (09)
  • [24] Fibrolamellar hepatocellular carcinoma treated with atezolizumab and bevacizumab: two case reports
    Al Zahrani, Ali
    Alfakeeh, Ali
    JOURNAL OF MEDICAL CASE REPORTS, 2021, 15 (01)
  • [25] Rechallenge With Lenvatinib After Atezolizumab Plus Bevacizumab Treatment for Hepatocellular Carcinoma
    Komatsu, Shohei
    Yano, Yoshihiko
    Kido, Masahiro
    Kuramitsu, Kaori
    Gon, Hidetoshi
    Fukushima, Kenji
    Urade, Takeshi
    So, Shinichi
    Yamamoto, Atsushi
    Goto, Tadahiro
    Yanagimoto, Hiroaki
    Toyama, Hirochika
    Ueda, Yoshihide
    Kodama, Yuzo
    Fukumoto, Takumi
    ANTICANCER RESEARCH, 2022, 42 (11) : 5479 - 5486
  • [26] Management of portal hypertension in patients treated with atezolizumab and bevacizumab for hepatocellular carcinoma
    Ollivier-Hourmand, Isabelle
    Allaire, Manon
    Cervoni, Jean Paul
    JOURNAL OF HEPATOLOGY, 2022, 77 (02)
  • [27] Adjuvant Atezolizumab-Bevacizumab after Resection or Ablation for Hepatocellular Carcinoma
    Kudo, Masatoshi
    LIVER CANCER, 2023, 12 (03) : 189 - 197
  • [28] Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab
    Yano, Shigeki
    Kawaoka, Tomokazu
    Johira, Yusuke
    Miura, Ryoichi
    Kosaka, Masanari
    Shirane, Yuki
    Murakami, Serami
    Amioka, Kei
    Naruto, Kensuke
    Ando, Yuwa
    Kosaka, Yumi
    Yamaoka, Kenji
    Kodama, Kenichiro
    Uchikawa, Shinsuke
    Fujino, Hatsue
    Ohno, Atsushi
    Nakahara, Takashi
    Murakami, Eisuke
    Okamoto, Wataru
    Yamauchi, Masami
    Imamura, Michio
    Mori, Keiichi
    Arihiro, Kouji
    Kuroda, Shintaro
    Kobayashi, Tsuyoshi
    Ohdan, Hideki
    Aikata, Hiroshi
    MEDICINE, 2021, 100 (42) : E27576
  • [29] Bayesian Analysis Supports Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
    Rizzo, Alessandro
    Ricci, Angela Dalia
    Brandi, Giovanni
    LIVER CANCER, 2022, 11 (02) : 180 - 181
  • [30] Neoadjuvant atezolizumab plus bevacizumab prior liver transplantation for hepatocellular carcinoma
    Tabrizian, Parissa
    Marino, Rebecca
    Bhoori, Sherrie
    Zeitlhoefler, Marcus
    Mehta, Neil
    Banz, Vanessa
    Gruttadauria, Salvatore
    Iavarone, Massimo
    Mazzarelli, Chiara
    Simonotti, Nicolo
    Yao, Francis
    Mazzaferro, Vincenzo
    Llovet, Josep M.
    JHEP REPORTS, 2025, 7 (02)
12345